IP Library Granted Patent US 9,814,580
Granted Patent B2
US 9,814,580 · App. 14/687,963 · Granted Nov 14, 2017

Joint repair using mesenchymal stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,814,580
App. No.
14/687,963
Granted
Nov 14, 2017
Kind
B2
Abstract

A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.

Claims (29)

1. A method of repairing damaged meniscal tissue in a joint of an animal with osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis, comprising:

administering directly to the joint via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to repair damaged meniscal tissue in the joint of the animal, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and

wherein the suspension is administered in the absence of a scaffold.

2. The method of claim 1 , wherein said mesenchymal stem cells differentiate into meniscal tissue.

3. The method of claim 1 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

4. The method of claim 1 , wherein said joint is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

5. The method of claim 1 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

6. A method of repairing damaged meniscal tissue in a joint to reduce joint pain in a human, comprising:

administering via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to reduce joint pain, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and wherein the suspension is administered in the absence of a scaffold.

7. The method of claim 6 , wherein said mesenchymal stem cells regenerate meniscal tissue between opposing bone or osteochondral surfaces.

8. The method of claim 6 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

9. The method of claim 6 , wherein said joint is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

10. The method of claim 6 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

11. A method of repairing damaged meniscal tissue in a joint to prevent osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis at a site damaged by meniscal injury in a human, comprising:

administering via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to prevent osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and wherein the suspension is administered in the absence of a scaffold.

12. The method of claim 11 , wherein said mesenchymal stem cells regenerate meniscal tissue between opposing bone or osteochondral surfaces.

13. The method of claim 11 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

14. The method of claim 11 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

15. The method of claim 11 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

16. A method of repairing damaged meniscal tissue in a joint to reduce osteophyte formation at a site damaged by meniscal injury in a human, comprising:

administering via intra-articular injection a suspension comprising isolated allogeneic mesenchymal stem cells in an amount effective to reduce osteophyte formation at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, and wherein the suspension is administered in the absence of a scaffold.

17. A method of repairing damaged meniscal tissue in a joint of an animal with osteoarthritis, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, or juvenile arthritis, comprising:

injecting a suspension of isolated allogeneic mesenchymal stem cells directly to the joint via intra-articular injection

wherein the allogeneic mesenchymal stern cells are in an amount effective to repair damaged meniscal tissue in the joint of the animal, and wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue.

18. The method of claim 17 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

19. The method of claim 17 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

20. The method of claim 17 , wherein the mesenchymal stem cells are present in the suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells and the mesenchymal stem cells are expanded in culture.

21. The method of claim 1 , wherein the animal is a human.

22. The method of claim 17 , wherein the animal is a human.

Assignments (4)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2017
From: OSIRIS THERAPEUTICS
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 043179/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2017
From: BARRY, FRANCIS P.; MURPHY, J. MARY; DEANS, ROBERT; FINK, DAVID J.; MOSELY, ANNEMARIE
To: OSIRIS THERAPEUTICS
Reel/Frame 043077/0371 →